In vivo and in vitro antidiabetic effects of citrus flavonoids; a study on the mechanism of action

International Journal of Diabetes in Developing Countries

Volumn 35, Issue 3, 2015, Pages 250-263

  Mahmoud, Ayman M ^a   Ahmed, Osama M ^a   Ashour, Mohamed B ^a   Abdel Moneim, Adel ^a  

^a BENI SUEF UNIVERSITY   (Egypt)

Author keywords

Citrus flavonoids; GLUT4; Hesperidin; HFD STZ diabetes; Insulin release; Naringin

Indexed keywords

EID: 84944453438     PISSN: 09733930     EISSN: 19983832     Source Type: Journal    
DOI: 10.1007/s13410-014-0268-x     Document Type: Article

References (84)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33 Suppl 1:S62–9.
2. Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev. 2008;29:351–66.
3. Bolzán AD, Bianchi MS. Genotoxicity of streptozotocin. Mutat Res. 2002;512:121–34.
4. Kim MJ, Ryu GR, Chung JS, Sim SS, Min Dos Rhie DJ. Protective effect of epicatechin against the toxic effects of STZ on rat pancreatic islets: in vivo and in vitro. Pancreas. 2003;26:292–9.
5. Kumar GPS, Arulselvan P, Kumar DS, Subramanian SP. Anti-diabetic activity of fruits of Terminalia chebula on streptozotocin induced diabetic rats. J Health Sci. 2006;52:283–91.
6. Zhang W, Zhao J, Wang J, Pang X, Zhuang X, Zhu X, et al. Hypoglycemic effect of aqueous extract of sea buckthorn (Hippophae rhamnoides L.) seed residues in streptozotocin-induced diabetic rats. Phytother Res. 2010;24:228–32.
7. Turk J, Corbett JA, Ramanadham S, Bohrer A, McDaniel ML. Biochemical evidence for nitric oxide formation from streptozotocin in isolated pancreatic islets. Biochem Biophys Res Commun. 1993;197:1458–64.
8. Tahrani AA, Piya MK, Kennedy A, Barnett AH. Glycaemic control in type 2 diabetes: targets and new therapies. Pharmacol Ther. 2010;125:328–61.
9. Chen H, Ward MH, Graubard BI. Dietary patterns and adenocarcinoma of the esophagus and distal stomach. Am J Clin Nutr. 2002;75:137–44.
10. Canadian Council on Animal Care. Guide to the care and use of experimental animals, vol. 2. Ottawa: CCAC; 1993.
11. Srinivasan K, Viswanand B, Asrat L, Kaul CL, Ramarao P. Combination of high-fat diet-fed and low dose of streptozotocin- treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res. 2005;52:313–20.
12. Reed MJ, Meszaros K, Entes LJ, Claypool MD, Pinkett JG, Gadbois TM, et al. A new rat model of type 2 diabetes, the fat-fed, streptozotocin- treated rat. Metabolism. 2000;49:1390–4.
13. Trinder P. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem. 1969;6:24–7.
14. Little RR, Wiedmeyer HM, England JD, Wilke AL, Rohlfing CL, Wians FH, et al. Interlaboratory standardization of measurements of glycohemoglobins. Clin Chem. 1992;38:2472–8.
15. Laakso M. How good a marker is insulin level for insulin resistance? Am J Epidemiol. 1993;137:959–65.
16. American Diabetic Association. Consensus development conference on insulin resistance. Diabetes Care. 1998;21:310–4.
17. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002;106:679–84.
18. Seifter S, Dayton S, Novic B, Muntwyler E. The estimation of glycogen with anthrone reagent. Arch Biochem. 1950;25:191–200.
19. Brandstrup N, Kirk JE, Bruni C. The hexokinase and phosphoglucoisomerase activities of aortic and pulmonary artery tissue in individuals of various ages. J Gerontol. 1997;12:166–71.
20. Koida H, Oda T. Pathological occurrence of glucose-6-phosphatase in serum in liver diseases. Clin Chim Acta. 1959;4:554–61.
21. Stallman W, Hers HG. The stimulation of liver phosphorylase b by AMP, fluoride and sulfate. A technical note of the specific determination of the a and b forms of liver glycogen phosphorylase. Eur J Biochem. 1975;54:341–50.
22. Gancedo JM, Gancedo C. Fructose-1,6-disphosphatase, phospho-fructokinase and glucose-6-phosphate dehydrogenase from fermenting and non fermenting yeasts. Arch Microbiol. 1971;76:132–8.
23. Munoz MA, Balon M, Fernandez C. Direct determination of inorganic phosphorus in serum with a single reagent. Clin Chem. 1983;29:372–4.
24. Zarzuelo A, Risco S, Gamez MJ, Jimenez J, Camara M, Martinez MA. Hypoglycemic action of Salvia lavandulifolia vahl. ssp. Oxyodon: a contribution to studies on the mechanism of action. Life Sci. 1990;47:909–15.
25. Howell SL, Taylor KW. Potassium ions and the secretion of insulin by islets of Langerhans incubated in vitro. Biochem J. 1968;108:17–24.
26. Pipeleers DG, Veld IPA, DeWinklem VM, Maes E, Schuit FC, Gepts W. A new in vitro model for the study of pancreatic A and B cells. Endocrinology. 1985;117:806–16.
27. Chomzynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Annu Rev Biochem. 1987;162:156–9.
28. PC-STAT. One way analysis of variance. Version IA (C). Program coded by M Roa, K. Blane and M Zonneberg. USA: University of Georgia; 1985.
29. Chandramohan G, Ignacimuthu S, Pugalendi KV. A novel compound from Casearia esculenta (Roxb.) root and its effect on carbohydrate metabolism in streptozotocin-diabetic rats. Eur J Pharmacol. 2008;590:437–43.
30. Saravanan G, Ponmurugan P. Ameliorative potential of Sallyl cysteine on oxidative stress in STZ induced diabetic rats. Chem Biol Interact. doi:10.1016/j.cbi.2010.10.001.
31. Ramachandran S, Asokkumar K, Uma Maheswari M, Ravi TK, Sivashanmugam AT, Saravanan S. et al. Investigation of antidiabetic, antihyperlipidemic, and in vivo antioxidant properties of Sphaeranthus indicus Linn. in type 1 diabetic rats: an identification of possible biomarkers. Evid Based Complement Alternat Med. doi:10.1155/2011/571721.
32. Arulrayan N, Rangasamy S, James E, Pitchai D. A database for medicinal plants used in the treatment of diabetes and its secondary complications. Bioinformatics. 2007;2:22–3.
33. Ayyanar M, Sankarasivaraman K, Ignacimuthu S. Traditional herbal medicines used for the treatment of diabetes among two major tribal groups in South Tamil Nadu, India. Ethnobot Leafl. 2008;12:276–80.
34. Reaven GM. Insulin resistance, hyperinsulinemia, hypertriglyceridemia and hypertension: parallels between human disease and rodent models. Diabetes Care. 1991;14:195–202.
35. Zhang F, Ye C, Li G, Ding W, Zhou W, Zhu H, et al. The rat model of type 2 diabetes mellitus and its glycometabolism characters. Exp Anim. 2003;52:401–7.
36. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation. Diabet Med. 1998;15:539–53.
37. Akhani SP, Vishwakarma SL, Goyal RK. Antidiabetic activity of Zingiber officinale in streptozotocin-induced type 1 diabetic rats. J Pharm Pharmacol. 2004;56:101–5.
38. Schaalan M, El-Abhar HS, Barakat M, El-Denshary ES. Westernized-like-diet-fed rats: effect on glucose homeostasis, lipid profile, and adipocyte hormones and their modulation by rosiglitazone and glimepiride. J Diabet Complicat. 2009;23:199–208.
39. Ahmed OM, Abdel-Moneim A, Abulyazid I, Mahmoud AM. Antihyperglycemic, antihyperlipidemic and antioxidant effects and the probable mechanisms of action of Ruta graveolens and rutin in Nicotinamide/streptozotocin diabetic albino rats. Diabetol Croat. 2010;39:15–32.
40. Farswan M, Mazumder PM, Parcha V. Modulatory effect of an isolated compound from Syzygium cumini seeds on biochemical parameters of diabetes in rats. Int J Green Pharm. 2009;3:128–33.
41. Beck-Nielsen H. Insulin resistance: organ manifestations and cellular mechanisms. Ugeskr Laeger. 2002;164:2130–5.
42. Gold AH. The effect of diabetes and insulin on liver glycogen synthetase activation. J Biol Chem. 1970;245:903–5.
43. Raju J, Gupta D, Rao AR, Yadava PK, Baquer NZ. Trigonella foenum graecum (fenugreek) seed powder improves glucose homeostasis in alloxan diabetic rat tissues by reserving the altered glycolytic, gluconeogenic and lipogenic enzymes. Mol Cell Biochem. 2001;224:45–51.
44. Powers AC (2005) Chapter 323. Diabetes mellitus. In: Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL. Harrison’s principles of internal medicine. 16th ed. The McGraw-Hill Companies, Inc; 2005.
45. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963;1:785–9.
46. Song H, Shojima N, Sakoda H, Ogiharaa T, Fujishiroa M, Katagiric H, et al. Resistin is regulated by C/EBPs, PPARs, and signal-transducing molecules. Biochem Biophys Res Commun. 2002;29:291–8.
47. Jung UJ, Lee MK, Jeong KS, Choi MS. The hypoglycemic effects of hesperidin and naringin are partly mediated by hepatic glucose-regulating enzymes in C57BL/KsJ-db/db mice. J Nutr. 2004;134:2499–503.
48. Pari L, Suman S. Antihyperglycemic and antilipidperoxidative effects of flavanoid naringin in streptozotocin-nicotinamide induced diabetic rats. Int J Biol Med Res. 2010;1:206–10.
49. Akiyama S, Katsumata S, Suzuki K, Ishimi Y, Wu J, Uehara M. Dietary hesperidin exerts hypoglycemic and hypolipidemic effects in streptozotocin-induced marginal type 1 diabetic rats. J Clin Biochem Nutr. 2010;46:87–92.
50. Sheela CG, Augusti KT. Antidiabetic effects of S-allyl cysteine sulphoxide isolated from garlic, Allium sativum Linn. Indian J Exp Biol. 1992;30:523–6.
51. Goldstein DE. How much do you know about glycated hemoglobin testing. Clin Diabetes. 1995;13:60–3.
52. Choi EJ. Antioxidative effects of hesperetin against 7,12-dimethylbenz(a)anthracene-induced oxidative stress in mice. Life Sci. 2008;82:1059–64.
53. Singh D, Chander V, Chopra K. Protective effect of naringin, a bioflavonoid on ferric nitrilotriacetate-induced oxidative renal damage in rat kidney. Toxicology. 2004;201:1–8.
54. Matthews CE, Suarez-Pinzon WL, Baust JJ, Strynadka K, Leiter EH, Rabinovitch A. Mechanisms underlying resistance of pancreatic islets from ALR/Lt mice to cytokine-induced destruction. J Immunol. 2005;175:1248–56.
55. Kanitkar M, Gokhale K, Galande S, Bhonde RR. Novel role of curcumin in the prevention of cytokine-induced islet death in vitro and diabetogenesis in vivo. Br J Pharmacol. 2008;155:702–13.
56. Mandrup-Poulsen T, Bendtzen K, Nielsen JH, Bendixen G, Nerup J. Cytokines cause functional and structural damage to isolated islets of Langerhans. Allergy. 1985;40:424–9.
57. Bendtzen K, Barington T, Mandrup-Poulsen T, Pedersen JG, Svenson M. Measurement of human IL-1 by LIF induction, pancreatic islet-cell cytotoxicity, and bone resorption. Lymphokine Res. 1986;5:S93–8.
58. Darville MI, Terryn S, Eizirik DL. An octamer motif is required for activation of the inducible nitric oxide synthase promoter in pancreatic beta cells. Endocrinology. 2004;145:1130–6.
59. Hayden MS, Ghosh S. Signaling to NF-κB. Genes Dev. 2004;18:2195–224.
60. Eizirik DL, Flodstrom M, Karlsen AE, Welsh N. The harmony of the spheres: inducible nitric oxide synthase and related genes in pancreatic beta cells. Diabetologia. 1996;39:875–90.
61. Heitmeier MR, Corbett JA. Cytotoxic role of nitric oxide in diabetes. In: Ignarro LG, editor. Nitric oxide biology and pathobiology. San Diego: Academic; 2000. p. 785–810.
62. Koster JC, Marshall BA, Ensor N, Corbett JA, Nichols CG. Targeted overactivity of beta cell K (ATP) channels induces profound neonatal diabetes. Cell. 2000;100:645–54.
63. Corbett JA, Wang JL, Sweetland MA, Lancaster JR, McDaniel ML. Interleukin 1 beta induces the formation of nitric oxide by beta-cells purified from rodent islets of Langerhans. Evidence for the beta-cell as a source and site of action of nitric oxide. J Clin Invest. 1992;90:2384–91.
64. Thomas HE, Darwiche R, Corbett JA, Kay TWH. Interleukin-1 plus gamma-interferon-induced pancreatic beta-cell dysfunction is mediated by beta-cell nitric oxide production. Diabetes. 2002;51:311–6.
65. Grover JK, Vats V, Rathi SS. Antihyperglycemic effect of Eugenia jambolana and Tinospora cordifolia in experimental diabetes and their effects on key metabolic enzymes involved in carbohydrate metabolism. J Ethnopharmacol. 2000;73:461–70.
66. Iynedjian PB, Gjinovci A, Renold AE. Stimulation by insulin of glucokinase gene transcription in liver of diabetic rats. J Biol Chem. 1988;263:740–4.
67. Lavoie L, Van de Werve G. Hormone-stimulated glucose production from glycogen in hepatocytes from streptozotocin diabetic rats. Metabolism. 1991;40:1031–6.
68. Ahmed OM. The hypoglycemic effect of curcumin and esculetin and their probable mechanisms of action in streptozotocin diabetic albino rats. J Egypt Ger Soc Zool. 2005;46:351–75.
69. Pari L, Murugan P. Effect of tetrahydrocurcumin on blood glucose, plasma insulin and hepatic key enzymes in streptozotocin induced diabetic rats. J Basic Clin Physiol Pharmacol. 2005;16:257–74.
70. Ahmed OM. Evaluation of the antihyperglycemic, antihyperlipidemic and myocardial enhancing properties of pioglitazone in diabetic and hyperthyroid rats. J Egypt Ger Soc Zool. 2006;51:253–78.
71. Cadefau J, Bollen M, Stalmans W. Glucose-induced glycogenesis in the liver involves the glucose-6-phosphate-dependent phosphorylation of glycogen synthase. Biochem J. 1997;322:745–50.
72. Bollen M, Keppens S, Stalmans W. Specific features of glycogen metabolism in the liver. Biochem J. 1998;336:19–31.
73. Jung UJ, Lee MK, Park YB, Kang MA, Choia MS. Effect of citrus flavonoids on lipid metabolism and glucose-regulating enzyme mRNA levels in type-2 diabetic mice. Int J Biochem Cell Biol. 2006;38:1134–45.
74. Berger J, Biswas C, Vicario PP, Strout HV, Saperstein R, Pilch PF. Decreased expression of the insulin-responsive glucose transporter in diabetes and fasting. Nature. 1989;340:70–2.
75. Camps M, Castelló A, Muñoz P, Monfar M, Testar X, Palacín M, et al. Effect of diabetes and fasting on GLUT-4 (muscle/fat) glucose-transporter expression in insulin-sensitive tissues. Heterogeneous response in heart, red and white muscle. Biochem J. 1992;282:765–72.
76. Garvey WT, Huecksteadt TP, Birnbaum MJ. Pretranslational suppression of an insulin-responsive glucose transporter in rats with diabetes mellitus. Science. 1989;245:60–3.
77. Sivitz WI, DeSautel SL, Kayano T, Bell BI, Pessin JE. Regulation of glucose transporter messenger RNA in insulin-deficient states. Nature. 1989;340:72–4.
78. Gerrits PM, Olson AL, Pessin JE. Regulation of the Glut4/ muscle-fat glucose transporter messenger-RNA in adipose tissue of insulin-deficient diabetic rats. J Biol Chem. 1993;268:640–4.
79. Ciaraldi TP, Kolterman OG, Scarlett JA, Kao M, Olefsky JM. Role of the glucose transport system in the postreceptor defect of non-insulin-dependent diabetes mellitus. Diabetes. 1982;31:1016–22.
80. Dohm GL, Tapscott EB, Pories WJ, Dabbs DJ, Flickinger EG, Meelheim D. An in vitro human muscle preparation suitable for metabolic studies. Decreased insulin stimulation of glucose transport in muscle from morbidly obese and diabetic subjects. J Clin Invest. 1988;82:486–94.
81. Andréasson K, Galuska D, Thörne A, Sonnenfeld T, Wallberg-Hen riksson H. Decreased insulin-stimulated 3-0-methylglucose transport in in vitro incubated muscle strips from type II diabetic subjects. Acta Physiol Scand. 1991;142:255–60.
82. Garvey WT, Maianu L, Huecksteadt TP, Birnbaum MJ, Molina JM, Ciaraldi TP. Pretranslational suppression of a glucose transporter protein causes insulin resistance in adipocytes from patients with non-insulin-dependent diabetes mellitus and obesity. J Clin Invest. 1991;87:1072–81.
83. Sinha MK, Raineri-Maldonado C, Buchanan C, Pories WJ, Carter-Su C, Pilch PF. Adipose tissue glucose transporters in NIDDM. Decreased levels of muscle/fat isoform. Diabetes. 1991;401:472–7.
84. Zorzano A, Santalucia A, Palacín M, Guma A, Camps M. Searching for ways to upregulate GLUT4 glucose transporter expression in muscle. Gen Pharmacol. 1998;31:705–13.